MedWatch

CEO of GN Hearing: R&D is back under control after restructuring

In 2021, hearing aid manufacturer GN Hearing’s R&D team missed a number of crucial deadlines. Since then, R&D has been restructured, which included letting the former head of the division go in October last year.

Gitte Aabo, CEO of GN Hearing | Photo: BUNDGAARD CARSTEN/ERH

When GN Hearing’s research and development unit missed several important deadlines last year, there were consequences.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs